MyDeltaCure
Register now!
Login
Chairs:
Heiner Wedemeyer and Pietro Lampertico
October 5-6, 2023
Courtyard Hotel Hannover Maschsee
Hannover, Germany - Arthur-Menge-Ufer 3
On this page you will find the Final Program of the Delta Cure...
Program
| 12:00 - 12:50 | Registration & Networking Lunch |
| 12:55 – 15:25 | RESIST D-SOLVE Symposium: Pathophysiology Chairs: Helenie Kefalakes (Germany); Thomas Schulz (Germany) |
| 12:55 | Introduction Helenie Kefalakes (Germany); Thomas Schulz (Germany) |
| 13:00 - 13:20 | HDV virology: New insightsStephan Urban (Germany) |
| 13:25 - 13:45 | Enhancing antiviral efficacy of NK cellsNiklas Björkström (Sweden) |
| 13:50 - 14:10 | How can anti-HBV immunity achieve HDV clearance?Markus Cornberg (Germany) |
| 14:15 - 14:35 | The anticipatory memory: Can B cells foresee the future?Ulrich Kalinke (Germany) |
| 14:40 - 15:00 | Epigenetic approaches to inhibit HDV-induced HCCJoachim Lupberger (France) |
| 15:05 - 15:15 | Short presentation: Mutiomics approach to decipher HDV viral controlLisa Sandmann (Germany) |
| 15:15 - 15:25 | Selected Poster Talk Single-cell resolved analysis of HDV infected stem cell-derived hepatocytes reveals restriction mechanisms and potential new host factorsArnaud Carpentier (Germany) |
| 15:25 - 15:50 | Poster Session & Coffee break |
| 15:50 - 16:00 | Welcome to Deltacure 2023 Heiner Wedemeyer (Germany); Pietro Lampertico (Italy); Niklas Luhmann, WHO (Switzerland) |
| 16:00 - 18:00 | SESSION I Natural History, Virology, Epidemiology & Diagnostics Chairs: Julie Lucifora (France); Pietro Lampertico (Italy) |
| 16:00 - 16:20 | Natural History of HDV infection: Who should be treated?Habiba Kamal (Sweden) |
| 16:25 - 16:45 | Epidemiology of HDV across the globe: How to enhance diagnosis and access to treatment Carla Coffin (Canada) |
| 16:50 - 17:10 | Molecular Epidemiology of HDV Infection in Asia: Changing epidemiology and Preventive Strategies Jaw-Ching Wu (Taiwan) |
| 17:15 - 17:25 | Selected Poster Talk HDV prevalence and genotypes in the Gambia: Presence of active infection despite serological negativity Amie Ceesay (France) |
| 17:25 - 17:45 | How new HDV RNA assays can accelerate diagnosticsTonya Hayden (USA) |
| 17:50 - 18:00 | Selected Poster Talk Improving access to HDV testing using dry blood spots Ségolène Brichler (France) |
| 18:00 - 18:30 | KEY NOTE LECTUREJohn Taylor (USA) |
| 18:30 - 18:40 | Delta Cure Award Ceremony |
| 18:40 - 18:45 | Summary & close of day 1 |
| 20:30 | Scientific Networking Dinner Special Dinner Talk: Michael Manns (Germany) |
| TREATMENT | |
| 08:30 - 10:00 | SESSION II Approved Clinical TherapiesChairs: Florin Caruntu (Romania); Cihan Yurdaydin (Turkey) |
| 08:30 - 08:50 | HDV evolution: Consequences for treatment response?Francisco Rodriguez-Frías (Spain) |
| 08:55 - 09:05 | Selected Poster Talk HDV quasispecies conservation and genetic evolution in presence of viral load fluctuation María Francesca Cortese (Spain) |
| 09:05 - 09:25 | Peg-IFN for patients with CHD: efficacy and long-term outcomesDominique Roulot (France) |
| 09:30 - 09:40 | Selected Poster Talk PegIFNα treatment in NUC-suppressed HBV/HDV-infected humanized mice reduces HDV infection below the limit of quantificationAnnika Volmari (Germany) |
| 09:40 - 10:00 | Bulevirtide treatment: New study resultsMaria Buti (Spain) |
| 10:05 - 10:30 | Poster Session & Coffee Break |
| 10:30 - 12:30 | SESSION III Real World Data & Mechanistic InsightsChairs: Tarik Asselah (France); Maurizia Brunetto (Italy) |
| 10:30 - 10:50 | Real world data on bulevirtide treatment responseElisabetta Degasperi (Italy) |
| 10:55 - 11:05 | Selected Poster Talk Real-world experience from off-label bulevirtide treatment for chronic hepatitis D in patients with decompensated liver disease Christopher Dietz-Fricke (Germany) |
| 11:05 - 11:25 | Combination of bulevirtide and Peg-IFNVictor de Ledinghen (France) |
| 11:30 - 11:50 | Mechanistic insights into BLV-induced HDV clearanceLena Allweiss (Germany) |
| 11:55 - 12:05 | Selected Poster Talk Long-term outcome of hepatitis delta in different regions world-wide: results of the Hepatitis Delta International Network (HDIN) Anika Wranke (Germany) |
| 12:05 - 12:25 | Can T cells recover under new anti-HDV treatments?Christoph Neumann-Haefelin (Germany) |
| 12:30 - 13:30 | Poster Session & Lunch |
| 13:30 - 15:30 | SESSION IV Therapies in DevelopmentChairs: Maura Dandri (Germany); Jeffrey Glenn (USA) |
| 13:30 - 13:50 | Efficacy of siRNAs and monoclonal antibodies in chronic hepatitis DFabien Zoulim (France) |
| 13:55 - 14:05 | Selected Poster Talk VIR-2218 and VIR-3434 therapy is efficacious in preclinical models of hepatitis delta virus infection Florian Lempp (Germany) |
| 14:05 - 14:25 | New insights on IFNlambda and Lonafarnib in achieving HDV clearanceOhad Etzion (Israel) |
| 14:30 - 14:50 | How can NAPs be used to achieve HDV control?Christiane Stern (France) |
| 14:55 - 15:05 | Selected Poster Talk Disease progression among commercially insured hepatitis delta virus infected patients in the United States Marvin Rock (USA) |
| 15:00 - 15:30 | Round Table DiscussionModerators: Pietro Lampertico and Heiner Wedemeyer |
| Expert Panel: Kosh Agarwal (United Kingdom); Soo Aleman (Sweden); Robert Gish (USA) | |
| 15:30 - 15:45 | Summary, Abstract Awards & Farewell |
